Discovery Parks | 2008 Discovery Parks Tenant News

2008 News Archive

December 19 Amorfix Life Sciences Blood Test for vCJD Achieves 100% Accuracy
December 11 Amorfix Life Sciences Amorfix Receives Fourth Biogen Idec Investment
November 26 Amorfix Life Sciences Amorfix Successfully Completes ALS Drug Discovery Program
November 17 Amorfix Life Sciences Amorfix Receives Third Biogen Idec Investment - Biogen Idec Retains Option to License to Amorfix ALS Technology
November 6 Amorfix Life Sciences Amorfix Announces Fiscal 2009 Second Quarter Results
October 20 Amorfix Life Sciences Amorfix is First Company in World to Show Preclinical Efficacy Using Monoclonal Anitbodies Targeting Misfolded Regions of Disease-Causing Proteins
October 17 Amorfix Life Sciences Amorfix vCJD Assay Achieves 100% Sensitivity and 100% Specificity on 1,000 Fresh Samples from UK Blood Donors
October 8 Amorfix Life Sciences Amorfix Sheep Scrapie Results from Blinded Panels Presented at International Prion Conference
September 23 Amorfix Life Sciences Amorfix Sets Up vCJD Blood Screening Assay in UK and Begins to Test Blood Donor Samples
September 12 Amorfix Life Sciences Amorfix Reports New Finding for vCJD Blood Screening Assay and Provides Corporate Update
September 9 Amorfix Life Sciences Amorfix Provides Corporate Update on Regulatory Process and Manufacturing for vCJD Diagnostic
August 19 Amorfix Life Sciences Amorfix to set up vCJD Assay in UK to continue validation process
June 24 Discovery Parks Vancouver Tech Park Developer Recognized for Green Building Leadership
May 20 Discovery Parks Discovery Parks receives energy conservation award
May 20 Discovery Parks Discovery Parks Trust Recognized for Green Building Leadership
April 16 Chemokine Therapeutics Chemokine Therapeutics Announces New President and Chief Executive Officer
April 7 Chemokine Therapeutics Chemokine Therapeutics Announces 2007 Financial Operating Results
March 17 Cardiome Cardiome announces positive interim phase 2b results for oral vernakalant and engages Merrill Lynch as strategic advisor
February 28 Chemokine Therapeutics Chemokine Therapeutics Announces the Publication of Study Results
February 21 Chemokine Therapeutics Chemokine Therapeutics announces three abstracts accepted for presentation at the AACR annual meeting on its lead drug candidate CTCE-9908
February 11 Amorfix Life Sciences Amorfix presents results from British blinded panel of spiked Human blood samples
February 8 Amorfix Life Sciences Amorfix announces third quarter fiscal 2008 results
February 1 Amorfix Life Sciences UK Government clarifies process to verify a blood test for vCJD and releases Amorfix blinded panel results
January 21 Cardiome Cardiome and Astellas announce regulatory update
January 4 Amorfix Life Sciences Amorfix Life Sciences appoints Aziz Mekouar as a member of board of directors